What is HC Wainwright’s Estimate for Korro Bio Q3 Earnings?

Posted by Brenda Bartman on Aug 11th, 2026

Korro Bio, Inc. (NASDAQ:KRRO – Free Report) – Stock analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for shares of Korro Bio in a research report issued on Friday, August 7th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($1.12) for the quarter, up from their prior forecast of ($1.38). HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($5.14) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2026 earnings at ($1.16) EPS, FY2026 earnings at ($4.88) EPS, Q1 2027 earnings at ($1.25) EPS, Q2 2027 earnings at ($1.22) EPS, Q3 2027 earnings at ($1.26) EPS, Q4 2027 earnings at ($1.31) EPS and FY2027 earnings at ($5.04) EPS.

Several other research firms have also weighed in on KRRO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a report on Monday, July 6th. Wall Street Zen upgraded Korro Bio from a “strong sell” rating to a “sell” rating in a report on Saturday. Lifesci Capital upgraded Korro Bio to a “strong-buy” rating in a research report on Friday, May 29th. JonesTrading raised Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Finally, Citigroup initiated coverage on Korro Bio in a research note on Monday, May 18th. They issued a “buy” rating and a $21.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.71.

Get Our Latest Research Report on KRRO

Korro Bio Trading Up 1.8%

Korro Bio stock opened at $13.49 on Tuesday. The company has a 50-day moving average price of $12.20 and a 200 day moving average price of $12.12. Korro Bio has a 12-month low of $5.20 and a 12-month high of $55.89. The stock has a market cap of $198.71 million, a P/E ratio of -1.35 and a beta of 3.04.

Korro Bio (NASDAQ:KRRO – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.07) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.27. Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 114.26%. The firm had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $0.21 million.

Insider Transactions at Korro Bio

In related news, insider Loic A. Vincent sold 3,418 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $10.83, for a total transaction of $37,016.94. Following the completion of the transaction, the insider directly owned 18,297 shares in the company, valued at $198,156.51. This trade represents a 15.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ram Aiyar sold 15,152 shares of Korro Bio stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $12.98, for a total value of $196,672.96. Following the completion of the transaction, the chief executive officer directly owned 74,848 shares of the company’s stock, valued at approximately $971,527.04. This represents a 16.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 306,026 shares of company stock worth $4,309,637 over the last quarter. 4.80% of the stock is owned by corporate insiders.

Institutional Trading of Korro Bio

Several hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. acquired a new position in shares of Korro Bio in the third quarter valued at approximately $39,000. Wells Fargo & Company MN boosted its position in Korro Bio by 45.5% in the 4th quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after buying an additional 2,352 shares during the period. Guggenheim Capital LLC acquired a new position in shares of Korro Bio in the fourth quarter worth $84,000. Jain Global LLC acquired a new position in shares of Korro Bio in the fourth quarter worth $85,000. Finally, Deutsche Bank AG increased its position in shares of Korro Bio by 241.9% during the fourth quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock worth $102,000 after acquiring an additional 9,027 shares during the period. Institutional investors and hedge funds own 13.18% of the company’s stock.

About Korro Bio

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.